Pharmacokinetics, pharmacodynamics, and safety of a prostaglandin D2 receptor antagonist.

@article{Lai2008PharmacokineticsPA,
  title={Pharmacokinetics, pharmacodynamics, and safety of a prostaglandin D2 receptor antagonist.},
  author={Eseng Lai and Larissa A Wenning and Tami M Crumley and Inge de Lepeleire and Fz Liu and Jay N de Hoon and Anne van Hecken and Marleen Depr{\'e} and Dawud Hilliard and Hallie Greenberg and Gerard M. O'neill and Kathleen M. Metters and Keith M. Gottesdiener and John A. Wagner},
  journal={Clinical pharmacology and therapeutics},
  year={2008},
  volume={83 6},
  pages={
          840-7
        }
}
Laropiprant is a selective antagonist of the prostaglandin D(2) (PGD(2)) receptor subtype 1 (DP1). Three double-blind, randomized, placebo-controlled studies evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of laropiprant in healthy male volunteers. Single doses up to 900 mg and multiple doses up to 450 mg were generally well tolerated. Laropiprant exhibited dose-proportional pharmacokinetics. Oral absorption is rapid (T(max)=0.8-2.0 h… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 21 CITATIONS

Laropiprant attenuates EP3 and TP prostanoid receptor-mediated thrombus formation

  • BMC Pharmacology and Toxicology
  • 2012
VIEW 6 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Extended-Release Niacin (Nicotinic Acid)/Laropiprant

VIEW 7 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

Extended-release niacin with laropiprant : a review on efficacy, clinical effectiveness and safety.

  • Expert opinion on pharmacotherapy
  • 2012
VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Similar Papers

Loading similar papers…